Nephrology

Several mobile apps effectively improved medication adherence in patients with CKD, posing important implications for their impact on clinical outcomes.

Kraus explains current unmet needs in IgA nephropathy and what sibeprenlimab may offer based on the phase 3 VISIONARY study.

Tumlin reviews findings from a posthoc analysis of DUPLEX demonstrating sparsentan’s impact on partial remission, complete remission, and kidney failure.

Black patients disproportionately started dialysis at low-quality facilities and were less likely to have nephrologists with high-quality primary facilities.

Lafayette reflects on recent therapeutic advances in IgA nephropathy and looks ahead to other renal pipeline developments he’s looking forward to in 2025.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

Lafayette describes ongoing unmet needs in IgAN care and how the growing understanding of disease pathogenesis has informed drug development.

Most patients preferred OLC over their previous phosphate binder, and pill number and size were identified as barriers to phosphate binder adherence.

Electronic health interventions improved medication adherence in kidney transplant recipients, with potential implications for improving patient outcomes.

Study findings suggest significant socioeconomic disparities in preemptive kidney transplantation rates in children and the need for targeted interventions.

Our Q1 recap for nephrology spotlights regulatory updates, new clinical trial data, and advancements in xenotransplant.

Data from nearly half a dozen trials suggests steroidal MRAs may provide little benefit in kidney transplant patients.

Using CURE-CKD Registry data, the analysis showed relatively rapid-onset CKD was common in people with prediabetes, especially with hypertension or ASCVD.

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

Study findings suggest COVID-19 is linked to a greater risk of long-term kidney dysfunction and new-onset advanced CKD than influenza.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.

The new guideline provides healthcare providers, people living with ADPKD, and stakeholders with practical tools to improve diagnosis, care, and treatment.

The report acknowledges the global health challenge of CKD-MBD, and its effect on both skeletal and cardiovascular systems in people with CKD.

A trio of nephrology experts discuss the significance of iptacopan’s FDA approval as the first treatment for C3G.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

Lerma discusses the current treatment landscape for IgA nephropathy and what role APRIL inhibition may play in treating IgAN.

The submission is supported by results from the phase 3 DUPLEX Study and the phase 2 DUET Study in adult and pediatric patients with FSGS.